Therapeutic Effects of Prolonged Cannabidiol Treatment on Psychological Symptoms and Cognitive Function in Regular Cannabis Users: A Pragmatic Open-Label Clinical Trial

Abstract

Introduction:

Chronic cannabis use has been associated with impaired cognition and elevated psychological symptoms, particularly psychotic-like experiences. While Δ⁹-tetrahydrocannabinol (THC) is thought to be primarily responsible for these deleterious effects, cannabidiol (CBD) is purported to have antipsychotic properties and to ameliorate cognitive, symptomatic, and brain harms in cannabis users. However, this has never been tested in a prolonged administration trial in otherwise healthy cannabis users. Here, we report the first study of prolonged CBD administration to a community sample of regular cannabis users in a pragmatic trial investigating potential restorative effects of CBD on psychological symptoms and cognition.

Materials and Methods:

Twenty frequent cannabis users (16 male, median age 25 years) underwent a 10-week open-label trial of 200 mg of daily oral CBD treatment, while continuing to use cannabis as usual. The majority of participants were daily cannabis users who had used cannabis for several years (median 5.5 years of regular use). Participants underwent psychological and cognitive assessments at baseline (BL) and post-treatment (PT) and were monitored weekly throughout the trial.

Results:

CBD was well tolerated with no reported side effects; however, participants retrospectively reported reduced euphoria when smoking cannabis. No impairments to cognition were found, nor were there deleterious effects on psychological function. Importantly, participants reported significantly fewer depressive and psychotic-like symptoms at PT relative to BL, and exhibited improvements in attentional switching, verbal learning, and memory. Increased plasma CBD concentrations were associated with improvements in attentional control and beneficial changes in psychological symptoms. Greater benefits were observed in dependent than in nondependent cannabis users.

Conclusions:

Prolonged CBD treatment appears to have promising therapeutic effects for improving psychological symptoms and cognition in regular cannabis users. Our findings require replication given the lack of a placebo control in this pragmatic trial, but suggest that CBD may be a useful adjunct treatment for cannabis dependence.

Get full access to this article

View all access options for this article.

References

Volkow

, Baler

, Compton

, et al. Adverse health effects of marijuana use. N Engl J Med. 2014; 370:2219–2227.

Volkow

, Swanson

, Evins

, et al. Effects of cannabis use on human behavior, including cognition, motivation, and psychosis: a review. JAMA Psychiatry. 2016; 73:292–297.

Di Forti

, Marconi

, Carra

, et al. Proportion of patients in south London with first-episode psychosis attributable to use of high potency cannabis: a case-control study. Lancet Psychiatry. 2015; 2:233–238.

Moore

, Zammit

, Lingford-Hughes

, et al. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet. 2007; 370:319–328.

Broyd

, van Hell

, Beale

, et al. Acute and chronic effects of cannabinoids on human cognition-a systematic review. Biol Psychiatry. 2016; 79:557–567.

Solowij

, Michie

. Cannabis and cognitive dysfunction: parallels with endophenotypes of schizophrenia?. J Psychiatry Neurosci. 2007; 32:30–52.

Lorenzetti

, Solowij

, Yücel

. The role of cannabinoids on neuroanatomical alterations in cannabis users. Biol Psychiatry. 2016; 79:e17–e31.

Bhattacharyya

, Crippa

, Martin-Santos

, et al. Imaging the neural effects of cannabinoids: current status and future opportunities for psychopharmacology. Curr Pharm Des. 2009; 15:2603–2614.

Martin-Santos

, Crippa

, Batalla

, et al. Acute effects of a single, oral dose of d9-tetrahydrocannabinol (THC) and cannabidiol (CBD) administration in healthy volunteers. Curr Pharm Des. 2012; 18:4966–4979.

10.

Pertwee

. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta(9)-tetrahydrocannabinol, cannabidiol and delta(9)-tetrahydrocannabivarin. Br J Pharmacol. 2008; 153:199–215.

11.

Osborne

, Solowij

, Weston-Green

. A systematic review of the effect of cannabidiol on cognitive function: relevance to schizophrenia. Neurosci Biobehav Rev. 2017; 72:310–324.

12.

McPartland

, Duncan

, Di Marzo

, et al. Are cannabidiol and Δ9‐tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review. Br J Pharmacol. 2015; 172:737–753.

13.

Laprairie

, Bagher

, Kelly

, et al. Cannabidiol is a negative allosteric modulator of the type 1 cannabinoid receptor. Br J Pharmacol. 2015; 172:4790–4805.

14.

Morgan

, Schafer

, Freeman

, et al. Impact of cannabidiol on the acute memory and psychotomimetic effects of smoked cannabis: naturalistic study. Br J Psychiatry. 2010; 197:285–290.

15.

Morgan

, Curran

. Effects of cannabidiol on schizophrenia-like symptoms in people who use cannabis. Br J Psychiatry. 2008; 192:306–307.

16.

Schubart

, Sommer

, van Gastel

, et al. Cannabis with high cannabidiol content is associated with fewer psychotic experiences. Schizophr Res. 2011; 130:216–221.

17.

Demirakca

, Sartorius

, Ende

, et al. Diminished gray matter in the hippocampus of cannabis users: possible protective effects of cannabidiol. Drug Alcohol Depend. 2011; 114:242–245.

18.

Yücel

, Lorenzetti

, Suo

, et al. Hippocampal harms, protection and recovery following regular cannabis use. Transl Psychiatry. 2016; 6:e71–0.

19.

Fadda

, Robinson

, Fratta

, et al. Differential effects of THC- or CBD-rich cannabis extracts on working memory in rats. Neuropharmacology. 2004; 47:1170–1179.

20.

Vann

, Gamage

, Warner

, et al. Divergent effects of cannabidiol on the discriminative stimulus and place conditioning effects of delta(9)-tetrahydrocannabinol. Drug Alcohol Depend. 2008; 94:191–198.

21.

Malone

, Jongejan

, Taylor

. Cannabidiol reverses the reduction in social interaction produced by low dose delta(9)-tetrahydrocannabinol in rats. Pharmacol Biochem Behav. 2009; 93:91–96.

22.

Wolf

, Bick-Sander

, Fabel

, et al. Cannabinoid receptor CB1 mediates baseline and activity-induced survival of new neurons in adult hippocampal neurogenesis. J Cell Commun Signal. 2010; 8:1–2.

23.

Bhattacharyya

, Morrison

, Fusar-Poli

, et al. Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacology. 2010; 35:764–774.

24.

Englund

, Morrison

, Nottage

, et al. Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment. J Psychopharmacol. 2013; 27:19–27.

25.

Degenhardt

, Coffey

, Romaniuk

, et al. The persistence of the association between adolescent cannabis use and common mental disorders into young adulthood. Addiction. 2013; 108:124–133.

26.

Lev-Ran

, Roerecke

, Le Foll

, et al. The association between cannabis use and depression: a systematic review and meta-analysis of longitudinal studies. Psychol Med. 2014; 44:797–810.

27.

Solowij

, Jones

, Rozman

, et al. Verbal learning and memory in adolescent cannabis users, alcohol users and non-users. Psychopharmacology (Berl). 2011; 216:131–144.

28.

Takagi

, Lubman

, Walterfang

, et al. Corpus callosum size and shape alterations in adolescent inhalant users. Addict Biol. 2013; 18:851–854.

29.

Sheehan

, Lecrubier

, Sheehan

, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998; 59 Suppl 20:22–33.

30.

Allsop

, Norberg

, Copeland

, et al. The Cannabis Withdrawal Scale development: patterns and predictors of cannabis withdrawal and distress. Drug Alcohol Depend. 2011; 119:123–129.

31.

Gossop

, Darke

, Griffiths

, et al. The severity of dependence scale (SDS): psychometric properties of the SDS in English and Australian samples of heroin, cocaine and amphetamine users. Addiction. 1995; 90:607–614.

32.

Martin

, Copeland

, Gates

, et al. The Severity of Dependence Scale (SDS) in an adolescent population of cannabis users: reliability, validity and diagnostic cut-off. Drug Alcohol Depend. 2006; 83:90–93.

33.

van der Pol

, Liebregts

, de Graaf

, et al. Reliability and validity of the Severity of Dependence Scale for detecting cannabis dependence in frequent cannabis users. Int J Methods Psychiatr Res. 2013; 22:138–143.

34.

Barkus

, Stirling

, Hopkins

, et al. Cannabis-induced psychosis-like experiences are associated with high schizotypy. Psychopathology. 2006; 39:175–178.

35.

Barkus

, Lewis

. Schizotypy and psychosis-like experiences from recreational cannabis in a non-clinical sample. Psychol Med. 2008; 38:1267–1276.

36.

Wechsler

. Wechsler abbreviated scale of intelligence (WASI). Harcourt Assessement: San Antonio, TX, 1999.

37.

Beck

, Ward

, Mendelson

. Beck depression inventory (BDI). Arch Gen Psychiatry. 1961; 4:561–571.

38.

Spielberger

, Gorsuch

, Lushene

, et al. Manual for the State-Trait Anxiety Inventory. Consulting Psychologists Press: Palo Alto, CA, 1983.

39.

Stefanis

, Hanssen

, Smirnis

, et al. Evidence that three dimensions of psychosis have a distribution in the general population. Psychol Med. 2002; 32:347–358.

40.

American Psychiatric Association (APA). Diagnostic and statistical manual of mental Disorders (4th ed. text rev.). APA: Washington, DC, 2000.

41.

Lezak

, Howieson

, Loring

. Neuropsychological assessment. 4th ed. Oxford University Press: Oxford, United Kingdom, 2004.

42.

Saunders

, Aasland

, Babor

, et al. Development of the alcohol use disorders identification test (AUDIT): WHO collaborative project on early detection of persons with harmful alcohol consumption—II. Addiction. 1993; 88:791–804.

43.

Sobell

, Sobell

. Timeline follow-back: a technique for assessing self-reported ethanol consumption. In Measuring alcohol consumption: psychological and biological methods ( Allen

, Litten

, eds.). Humana Press: Totowa, NJ, 1992, pp. 41–72.

44.

Leweke

, Piomelli

, Pahlisch

, et al. Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl Psychiatry. 2012; 2:e9–4.

45.

McGuire

, Robson

, Cubala

, et al. Cannabidiol (CBD) as an adjunctive therapy in schizophrenia: A multicentre randomized controlled trial. Am J Psychiatry. 2018; 175:225–231.

46.

Galettis

. Development of a simple LCMSMS method for THC and metabolites in plasma. Asia Pac J Clin Oncol. 2016; 12:13–34.

47.

Swift

, Copeland

, Hall

. Choosing a diagnostic cut-off for cannabis dependence. Addiction. 1998; 93:1681–1692.

48.

Simen

, Ma

, Svetnik

, et al. Efavirenz modulation of sleep spindles and sleep spectral profile. J Sleep Res. 2015; 24:66–73.

49.

Osborne

, Solowij

, Babic

, et al. Improved social interaction, recognition and working memory with cannabidiol treatment in a prenatal infection (poly I:C) rat model. Neuropsychopharmacology. 2017; 42:1447–1457.

50.

Overall

, Gorham

. The brief psychiatric rating scale. Psychol Rep. 1962; 10:799–812.

51.

McNair

, Lorr

, Droppleman

. Manual for the profile of mood states. educational and industrial testing services. Educational and Industrial Testing Services: San Diego, CA, 1971.

52.

Raine

. The SPQ: a scale for the assessment of schizotypal personality based on DSM-III-R criteria. Schizophr Bull. 1991; 17:55–5.